Plain language summary
Systemic sclerosis (SSc) is an uncommon condition that results in hard, thickened areas of skin and additional problems with internal organs and blood vessels. Interstitial lung disease (ILD) affects the tissue and space around the air sacs of the lungs and is one of the leading causes of death in patients with SSc. As such, it is important to understand how this condition manifests to better recognize and treat patients. We identified 50 papers published between January 2000 and February 2016 that assessed how common SSc and SSc-associated ILD (SSc-ILD) are and/or provided information on the affected patient populations as well as survival/mortality rates in these patients. We found that there was wide variation in the reported
Introduction
Systemic sclerosis (SSc) is a rare, heterogeneous autoimmune disease characterized by sclerodermatous skin changes, vasculopathy, and involvement of internal organs, including the lungs. 1 The etiology of SSc is largely unknown but is thought to involve both genetic and environmental factors. 2 The primary event in SSc pathogenesis is thought to be injury to endothelial cells; this is followed by aberrant vascular and immune responses that lead to the excessive deposition and accumulation of extracellular matrix. The resultant progressive tissue remodeling can destroy tissue architecture and cause loss of organ function. 3 Early studies consider the American College of Rheumatology (ACR) 1980 criteria to classify SSc. These require finding proximal involvement of the skin by sclerodermatous changes or two or more of the following minor criteria: sclerodactyly; digital pitting scars on the fingertips or loss of substance of the distal finger pad; or bilateral basilar pulmonary fibrosis. 4 However, as these criteria have low sensitivity, particularly in cases of early or mild SSc, and do not consider the assessment of serum antibodies or vasculopathy, 2 there have been subsequent attempts to improve on their limitations. The classification by LeRoy et al (1988 5 ) and the updated version by LeRoy and Medsger (2001 6 ) were used to distinguish the various cutaneous forms of the disease, depending on the extent of skin involvement. In patients with limited cutaneous SSc (lcSSc), skin sclerosis is distal and limited to the elbows, knees, and clavicles, whereas the diffuse cutaneous form of the disease (dcSSc) affects the whole body. 7 The classification by LeRoy and Medsger also proposes a limited SSc subset with healthy skin. 6 In 2013, a new 9-point classification system, endorsed by the ACR/European League Against Rheumatism (EULAR), was validated. This enabled the identification of early disease, thereby leading to earlier management, which may slow disease progression. 8 Organ involvement occurs early in the course of the disease. 9 The occurrence of associated complications is related to the severity and progressiveness of disease, with approximately 25% of the patients developing significant pulmonary involvement within 3 years of SSc diagnosis. 10 Interstitial lung disease (ILD) constitutes one of the most common types of direct pulmonary involvement in SSc patients, characterized by diffuse parenchymal infiltrative processes that may lead to fibrosis. ILD is most frequently observed in those with dcSSc 9, 11, 12 and is a major contributor to the morbidity and mortality associated with SSc. 1 There is currently no consensus on how ILD in SSc should be diagnosed, resulting in discrepancies in the assessment and reported frequency of occurrence of this complication. Diagnosis of SSc-associated ILD may be performed using several auxiliary diagnostic tools such as pulmonary function tests and chest high-resolution computed tomography (HRCT), with the latter generally accepted as the "gold standard" for evaluating the extent of lung involvement. 1, [13] [14] [15] [16] It should be noted that there is no systematic use of biopsies or histology to aid diagnosis due to the presence of an ILD-associated disease. The aim of therapeutic treatment for SSc and SScassociated ILD (SSc-ILD) is to improve quality of life by minimizing specific organ involvement and subsequent life-threatening diseases. In 2009, the EULAR and EULAR Scleroderma Trials and Research (EUSTAR) groups published evidence-based recommendations for the treatment of SSc. 17 The treatment of lung disease is not yet fully defined; however, immunosuppressive therapies are often used with the aim of reducing pulmonary interstitial inflammation. 18 Based on the results of the Scleroderma Lung Study II 19 and several other low-quality studies 20 that suggest that mycophenolate alone could control active ILD with a tolerable safety profile, most experts are transitioning from cyclophosphamide to this immunosuppressive therapy for long-term disease control. An update to the EULAR guidelines was published in 2016 to include new treatment options for SSc-related organ complications. It also provides direction for future clinical research in SSc. 21 It is important to gain further understanding of the SSc and SSc-ILD patient populations to better inform the diagnosis and treatment of these patients. In this paper, we present the results of a systematic review on the epidemiology of SSc and SSc-ILD, including data on prevalence, incidence, demographic profile, and survival and mortality.
Materials and methods

Search strategy
Literature searches were conducted using Medline and Embase electronic bibliographical databases. Search strategies combined thesaurus terms (MeSH and Emtree terms for Medline and Embase, respectively) and free-text keywords; full search strategies are provided in Tables S1-S9 . Independent searches were performed for SSc and SSc-ILD in both Europe and North America (United States and Canada) and results were restricted to studies published between January 1, 2000 and February 29, 2016.
In addition, using similar combinations of the previously defined keywords, pragmatic searches of web sources were conducted using Google and Google Scholar. Websites of relevant scientific societies, medical associations, and conference proceedings were also reviewed (Table S10) . Lastly, manual review of reference lists of included publications or relevant reviews was performed to maximize the comprehensiveness of the search.
Study selection process
Results from the literature searches were uploaded into EPPI-Reviewer 4 (Social Science Research Unit, UCL Institute of Education, University of London, UK). Duplicate publications were identified and excluded using an automated procedure followed by manual quality control. The titles and abstracts of all remaining publications were independently screened by two reviewers, with any conflicts resolved by a third reviewer, according to eligibility criteria. Inclusion criteria included: studies conducted in humans; studies on SSc or SSc-ILD; studies reporting epidemiologic data; studies conducted in, or reporting data from, European countries or North America (United States and Canada) (data for the rest of the world were not considered); and studies published in English, German, French, Spanish, Italian, or Portuguese. Exclusion criteria included: case reports, case series, and opinion pieces. Following screening, the eligibility of all identified publications was confirmed via an in-depth review of the full-text articles, if available.
Quality assessment
For all publications included in the review, a qualitative assessment of methodologic quality and individual risk of bias was performed considering criteria from the Newcastle-Ottawa scale (NOS; http://www.ohri.ca/pro grams/clinical_epidemiology/nosgen.pdf), the Preferred Reporting Items for Systematic Reviews and MetaAnalyses checklist (PRISMA; http://prisma-statement. org/documents/PRISMA%202009%20checklist.pdf) and expert review. In addition, a qualitative assessment of the quantity of available data was performed. For each dimension (prevalence, incidence, demographic profile, and survival and mortality) and region (Europe and North America), it was determined whether the available data were based on studies of "high," "medium," or "low" quality (Table 1) .
Results
In total, 1,637 publications were identified through literature searches conducted in Medline and Embase. After the removal of 249 duplicates and the exclusion of 1,229 publications following screening, 159 publications were assessed for eligibility (based on in-depth review of the full-text article, where available), of which 11 did not meet eligibility criteria, resulting in 148 publications undergoing quality assessment. Webbased searches and manual review of reference lists yielded one additional reference, providing a total of 149 sources from which data were extracted (Figure 1 ).
For the purposes of this paper, the presented results are restricted to 50 publications that included data on prevalence, incidence, demographic profile, and survival and mortality of the populations of interest, and an overview of all included publications is presented in Table S11 . Of these, 29 publications reported results from studies conducted in Europe, while 21 reported data for North America. Of note, only 16 of the identified studies included patients with SSc-ILD. Results of the quality assessment are presented in Table 2 , with the majority of evidence rating "medium" or "high" for both availability and quality.
Prevalence
A total of 18 studies were identified that assessed the prevalence of SSc across Europe and North America (Figure 2) . No dedicated studies reported prevalence data for SSc-ILD; however, seven studies were identified that reported the proportion of SSc patients who had, or were developing, ILD.
Europe
In Europe, 11 studies have been conducted to evaluate the prevalence of SSc ( No prevalence data specific to SSc-ILD were identified in the systematic review. Four publications did, however, describe the proportion of SSc patients who had, or were developing, ILD (Figure 3 ), of which one also reported the prevalence of SSc, thereby enabling an estimate of SSc-ILD prevalence to be derived. Over the period of 2010-2012, in a cohort study of 44 SSc patients conducted in Romania, ILD was reported to affect 36.4% of the patients (method of diagnosis not reported). 23 Similar findings were reported from a study including 204 SSc patients from the Royal National Hospital for Rheumatic Diseases connective tissue disease database in the UK between 1999 and 2000. It was estimated that 32.3% of the SSc patients also had ILD, diagnosed using HRCT or lung biopsy. 15 These results were also supported by findings from the Rheumatology Unit at Catania Hospital, Italy, where 32.6% of the 44 SSc patients diagnosed between 2006 and 2013 had co-morbid ILD (method of diagnosis not reported). 24 Based on these data, the proportion of ILD among SSc patients was estimated at~35% in Europe. However, the reported proportion of ILD among SSc patients in the Netherlands varied from 18.8% (diagnosed using total lung capacity <70% predicted) to 47.0% (diagnosed using HRCT score >3), when assessed using data from the Pulmonary Hypertension Screening, a Multidisciplinary Approach in Scleroderma (POEMAS) registry combined with nationwide questionnaires collected between 2005 and 2007. 16 Based on the reported prevalence of SSc in this study, the derived prevalence of SSc-ILD was estimated as 1.7-4.2 per 100,000 individuals. 16 
North America
Seven studies were identified that evaluated the overall prevalence of SSc in North America ( ), and British Columbia (6.4 per 100,000 men and 35.6 per 100,000 women 28 ) in 2007. As with Europe, no specific prevalence data were identified for SSc-ILD during the systematic review. Consequently, the proportion of SSc patients with, or developing, ILD was derived using reported data from three studies ( Figure 3) . A historical, population-based cohort study conducted in Olmsted County, MN, USA, identified 64 patients with SSc, of whom 30% developed ILD, as diagnosed by HRCT. 1 Higher proportions were, however, reported in other published studies. A medical chart review of 128 SSc patients from a single center between 2004 and 2014 reported 43.0% also had ILD, as diagnosed by HRCT. 13 In addition, in a cohort of 
Incidence
In total, nine studies reported data on the incidence of SSc in Europe and North America. As with prevalence, no studies specifically assessed the incidence of SSc-ILD. Only one European study reported the proportion of SSc patients who had, or were developing, ILD, therefore enabling the incidence of SSc-ILD to be estimated.
Europe
In Europe, five studies have been conducted to evaluate the overall incidence of SSc ( findings were reported in a Greek cohort study covering the period of 1981-2002, in which annual incidence was reported to be 0.2 and 1.9 per 100,000 men and women, respectively, and was highest in men aged >65 years (0.7 per 100,000) and women aged 45-64 years (3.9 per 100,000). 29 Conversely, an annual incidence of 0.3 (95% CI: 0.1-0.5) per million children (aged <16 years) was reported using data reported by members of specialist medical associations in the UK and Ireland over the period of 2005-2007. 30 Similar to prevalence, no specific incidence data were identified for SSc-ILD during the systematic review. Combining data from the POEMAS registry and nationwide questionnaires collected in the Netherlands in 2006, the incidence of SSc-ILD in Europe was then calculated using the reported incidence of SSc and the proportion of SSc patients with ILD. Thus, estimated annual incidence ranged from 0.1 to 0.4 per 100,000 individuals, when defined using total lung capacity <70% predicted or HRCT score >3, respectively. 16 
North America
Four studies have been conducted in North America, with results suggesting the incidence of SSc is similar to that in Europe (Table 4) . However, estimates were observed to vary according to the data source used, with studies based on health care databases providing higher annual estimates (3.6-5.6 per 100,000 individuals 25, 28 ) compared to medical chart review (1.4-2.4 per 100,000 individuals 1, 31 No incidence data specific to SSc-ILD in North America were identified through the systematic review. In addition, in this region, available data were insufficient to derive estimates of the incidence of this condition. 
Gender: North America
Similarly, a female predominance of SSc was reported in North America, with three studies reporting a greater proportion of women with the condition compared to men (Table 6) , with female:male ratios ranging from 4.6:1 to 15:1.
13,31
Female gender was also found to predominate in five studies assessing SSc-ILD patients in North America, with women representing 78% of a cohort of SSc patients with severe ILD from the PHAROS registry 39 and accounting for 89% of SSc-ILD patients who had undergone HRCT in a cross-sectional study conducted in Canada. 41 Additional publications from the United States 37, 38 and Canada 14 reported similar results (69%, 84%, and 86% female, respectively).
Ethnicity: Europe
In Europe, two studies considered ethnicity in relation to SSc. One study conducted within a French multi-ethnic county during 2001 reported higher SSc prevalence rates in individuals aged >15 years with a non-European ethnic background, compared to Europeans (21.1 per 100,000 vs 14.0 per 100,000, respectively). 40 Conversely, data from the connective tissue disease database at the University Hospital of Leicester in the UK identified 14% of the SSc patients as being South Asian, 58% as being Caucasian, and 3% as being black/African-American. 42 It should be considered that the reported ethnicity may be a function of the location of the study, so geography may have an influence on the observed results.
No publications reporting specific data on the influence of ethnicity in SSc-ILD were identified. In an analysis of Regarding the influence of ethnicity on SSc-ILD, only one publication was identified. The majority of SSc patients with severe ILD identified through the PHAROS registry were found to be Caucasian (63%; 24% black/ African-American; 11% Hispanic). 39 
Survival and mortality Europe
In Europe, 10 publications were identified that reported data on survival and mortality in patients with SSc. Patients with SSc were reported to have 5-and 10-year survival rates of 83-84% and 65-73%, respectively. 7, 29, 33 The reported standardized mortality ratio (SMR) ranged from 1.3 (95% CI: 1.0- Regarding SSc-ILD, three publications reporting European survival and mortality data were identified. In the UK, results from a cohort study of 40 patients with SSc-ILD over the period 2000-2009 reported a mean survival duration of 8.8 years and mortality rate of 70.9 per 1000 person-years (95% CI: 36.9-136.3). 35 In a second UK cohort of 36 SSc-ILD patients treated with intravenous cyclophosphamide (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) Few publications (n=16) reported findings specific to the SSc-ILD population. Data on prevalence and incidence were derived based on the proportion of SSc patients who also reported ILD; however, it should be considered that these estimates may not be fully representative of the overall SSc-ILD patient population. ILD was estimated to affect~35% of the SSc patients in Europe and~52% in North America; however, the method of ILD assessment may potentially contribute to differences in the observed frequencies. For example, when diagnosed via HRCT, ILD was estimated to affect 32.3-47.0% of the SSc patients in Europe; whereas only 18.8% of the patients were reported to be affected when diagnosed based on reduced lung function. 16 Based on the available data, SSc-ILD was calculated to have an estimated prevalence and annual incidence of 1.7-4.2 per 100,000 individuals and 0.1-0.4 per 100,000 individuals in Europe, respectively. Incidence estimates could not be obtained for North America due to lack of published data; however, based on reported data for SSc, it may be expected that SSc-ILD incidence rates would be similar to those observed in Europe. In both Europe and North America, a slightly higher mean age at diagnosis was observed in patients with SSc-ILD compared to those with SSc (46-61.8 years and 52.5-54.5 years, respectively). Similar gender ratios were observed in patients with SSc and SSc-ILD, with a female predominance in both Europe (75-82%) and North America (≥69%). Data from North America suggest that SSc-ILD and associated complications are observed most frequently in Caucasian patients; however, these data must be interpreted with caution due to the paucity of available information. Limited data on survival and mortality were available in patients with SSc-ILD; however, the presence of respiratory symptoms and reduced pulmonary function was reported to be associated with poorer prognosis. It should be considered that differences in the underlying patient populations, data sources, methodology, definitions, and diagnostic criteria existed between studies (Table S11) . Of the identified studies, 15 were based on chart review, eight on electronic medical records, six on administrative claims databases, five on disease registries, five on ad hoc data collection (data collected during medical examination or via questionnaires submitted to patients during follow-up in routine clinical practice), one on a questionnaire, one on a literature search, and nine on mixed data sources. In addition, 37 were cohort studies, 11 were cross-sectional studies, one was a survey, and one was a modeling analysis. Such differences may prevent direct comparison of data and likely resulted in large ranges and/or inconsistencies in epidemiologic estimates. In addition, differences in the period over which each study was performed and each epidemiologic variable was assessed (ranging from starting in 1972 to ending in 2015), and corresponding changes in SSc and SSc-ILD disease awareness, classification guidelines, diagnostic criteria, and disease management over time may have resulted in variation in estimates. Consistently higher prevalence and incidence estimates were reported when assessed using newer diagnostic classifications (Tables 3  and 4) , which allow for broader assessment of disease characteristics. For example, the prevalence of SSc in Sweden (2006-2010) was reported as 23.5 per 100,000 individuals based on the ACR 1980 diagnostic criteria and 30.5 per 100,000 individuals based on the ACR-EULAR 2013 criteria; corresponding incidence values were reported as 1.4 and 1.9 per 100,000 individuals, respectively. 57 Differences between demographic profiles of patients with SSc in different geographical regions were assessed in a prior systematic review. Differences in the mean age at the time of diagnosis, subsets of SSc, clinical characteristics, and presence of antibodies were found between Europe, North America, South America, Asia, and Australia. No information on prevalence, incidence, or survival was presented, and SSc-ILD was not specifically discussed; 58 however, similar to our review, important epidemiological geographical differences in SSc were observed. This systematic review also has some limitations. Although the majority of data were considered "medium" or "high" for both availability and quality of evidence in our review (Table 2) , the number of identified publications that assessed each epidemiologic category was relatively small (n=21, 10, 23, and 24 for prevalence, incidence, demographic profile, and survival and mortality, respectively). The identified studies included a range of sample sizes, with some including as few as seven patients. In addition, a quarter of the identified publications were in abstract format only (n=16), meaning limited methodologic and results data were included. Furthermore, publications were limited to those in English, German, French, Spanish, Italian, or Portuguese, and studies outside Europe or North America were not included, which may have restricted the available evidence.
This first systematic review on the epidemiology of SSc and SSc-ILD provides a useful overview. Additional evidence in relation to prevalence, incidence, demographic profile, and survival and mortality would be beneficial to gain a better understanding of the burden of SSc and SSc-ILD.
Conclusions
This systematic review confirms our assumptions that SSc and SSc-ILD are rare, with wide-ranging estimates of SSc prevalence and incidence reported across Europe and North America. Both SSc and SSc-ILD were reported to predominantly affect women, with cardiorespiratory manifestations associated with poorer prognosis. Additional observational studies would be beneficial to provide more accurate estimates of prevalence and incidence, as well as demographic and survival/mortality data. In particular, more epidemiologic information on patients with SSc-ILD would enable a deeper understanding of the burden and impact of this rare disease.
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